Connect with us

Healthcare

Poly Medicure Limited (POLYMED) breaks out, gains 5% intraday

Poly Medicure Limited (NSE: POLYMED) stock breaks out, moving up 5% intraday to ₹1750.5, clearing its 6M resistance trendline in the Healthcare sector.

preety tomer tradealone

Published

on

Poly Medicure Limited POLYMED breakout

Poly Medicure Limited (POLYMED) breaks out with a +5% gain, clearing its 6-month resistance trendline. The move is technical, driven by the stock’s breakout above the key ₹1330 resistance level, marking a 24.0% clear. Poly Medicure, a player in the healthcare sector specializing in medical instruments and supplies, saw its stock price surge, outperforming the broader sector which has been under pressure. This move appears company-specific, not a sector-wide rally.

Technical setup — trendlines & DMA

The current trendline structure shows a robust breakout. The 6-month support floor is at ₹1319.52, which the stock has surpassed by 24.62%, indicating strong upward momentum. Resistance was previously at ₹1329.79, which has now been broken by 24.03%. The 50-DMA at ₹1514.5 is below the 200-DMA at ₹1622.9, typically a bearish signal, but the stock is currently trading 10.01% above the 50-DMA and 2.66% above the 200-DMA, suggesting a stretched but positive move. The stock is in the middle third of its 52-week range, up 50% from the low and 24.4% below the high, implying there’s room for further upside but also potential for a pullback.

6M Trendline — Intraday Snapshot
BREAKOUT₹1,400₹1,500₹1,600₹1,70018 May2 Jun17 Jun2 Jul

Snapshot: ₹1,750.50 on 2026-07-02 (chart frozen at publication)

Fundamentals & business context

With a PE of 52.5, Poly Medicure’s valuation appears stretched given its 17.2% profit margin and 19.1% revenue CAGR. The market seems to be pricing in future growth, but the current earnings may not fully justify the high PE. Institutional ownership stands at 17.4%, indicating a cautious yet interested stance from smart money. There was no NSE catalyst today, reinforcing that the move is purely technical.

POLYMED
Holdings Analysis
Key strengths & risk signals
76
Overall
77
Fundamental
76
Technical
Risks (2)
NEGLIGIBLE DIVIDEND! 0.21% yield - little to no income.
WEAK YEAR! Stock declined 14.6% in the last year.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (1620.1) is above 200-day average (1541.0) - positive signal.
BREAKOUT! Stock has broken above resistance levels with momentum.
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.

Algorithmic scorecard

The overall algorithmic scorecard reflects a technically strong but fundamentally cautious profile. The strongest signals are the revenue and profit CAGRs, which stand at 19.1% and 22.7% respectively, indicating solid growth momentum. Additionally, the very low debt level with a D/E ratio of 0.07 points to excellent financial health. On the weaker side, the stock’s PEG ratio of 2.31 suggests it is overvalued relative to its growth rate, and the negligible dividend yield of 0.21% offers little income for investors. These factors highlight the need for cautious optimism.

Fundamental & Technical AnalysisNSE: POLYMED
76Overall
77Fundamental
76Technical
Growth Quality28 / 30
Revenue CAGR: 18.8% (VERY GOOD, 13/15). Profit CAGR: 21.6% (EXCELLENT, 15/15).
Profit Margin5 / 10
DECENT EFFICIENCY! 14.9% profit margin - acceptable profitability.
PEG Valuation7 / 10
OVERVALUED! PEG of 2.48 means expensive relative to growth rate.
Dividend Yield3 / 10
NEGLIGIBLE DIVIDEND! 0.21% yield - little to no income.
Debt / Equity10 / 10
VERY LOW DEBT! D/E of 0.08 - excellent financial health.
Public Holding14 / 20
MODERATE PUBLIC HOLDING! 26.82% public ownership - balanced ownership structure.
Stability10 / 10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Moving Averages12 / 10
BULLISH TREND! 50-day average (1620.1) is above 200-day average (1541.0) - positive signal.
Price Position8 / 10
STRONG POSITION! Current price (1681.2) is above both moving averages.
Trend Pattern20 / 20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance2 / 10
WEAK YEAR! Stock declined 14.6% in the last year.
Volume Sentiment20 / 30
BULLISH SENTIMENT! In last 30 days: 13 up days, 16 down days. Avg volume on up days: 94,072 vs down days: 85,535. Ratio: 1.1x
RSI3 / 5
NEUTRAL! RSI at 55.0 - balanced momentum.
52W Range3 / 5
MID RANGE! Trading at 59.2% of 52W range - neutral zone.
Momentum3 / 5
MIXED MOMENTUM! Price growth is inconsistent - 4.3% (1 week), 5.8% (1 month), -5.9% (3 months).
Beta / Volatility5 / 5
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.

Company outlook

Poly Medicure has guided for a revenue range of INR2,300 crores to INR2,400 crores for FY ’27 on a consolidated basis, up from INR1,875 crores in FY ’26. On a stand-alone basis, revenue is expected to be between INR1,900 crores and INR1,950 crores for FY ’27. The domestic business is projected to grow upwards of 20%, while the international business is expected to grow upwards of 15%. The company anticipates stand-alone EBITDA margins between 25% and 27%, and consolidated EBITDA margins between 23% and 25% for FY ’27. The Renal segment is guided for a 20% growth, and Citieffe is expected to see low double-digit growth in euro terms. The company plans to invest between INR200 crores and INR225 crores in capex this year, focusing on automation to offset wage revisions. Additionally, efforts are underway to integrate synergies and engineering work in India to enhance the margins of recently acquired companies, Citieffe and PendraCare.

Get all details on POLYMED — P&L, peers, shareholding and more on TradeAlone.

Healthcare

Themis Medicare Limited (themismed) Q2 FY27: Revenue Up 15%, Ebitda Positive

Themis Medicare Limited (THEMISMED) reports a 15% revenue increase in Q2 FY27, with EBITDA turning positive at 6.2% margin.

shalini shishodia tradealone

Published

on

Themis Medicare Limited Themismed Q2 FY27 Results

Themis Medicare Limited (THEMISMED) has announced its financial results for Q2 FY27, showcasing a strong turnaround with a 15.1% year-on-year revenue growth to ₹89.74 crore. This performance was led by a remarkable 71% rebound in the API business to ₹20 crore, while the Formulations business maintained steady revenue at ₹69 crore.

Financial Highlights

The company reported a return to operating profitability with an EBITDA of ₹5.58 crore at a 6.2% margin, compared to a loss in the year-ago quarter. The net profit after tax (PAT) stood at ₹7.06 crore against a loss last year. This improvement is attributed to the company’s focus on productivity and operational efficiency.

Segment Performance

Within Formulations, the Critical Care Division doubled its profit before tax (PBT) during the quarter, driven by Themiseal Gel’s encouraging month-on-month momentum. The Ortho and Gynecology Division also doubled its revenue, bolstered by strong traction in the hormonal portfolio and the integrated product strategy. The API business demonstrated a robust recovery, gaining healthy revenue visibility.

For H1 FY27, revenue stood at ₹176.70 crore, with the strong performance in Q2 helping offset a more challenging first quarter. The company remains optimistic about the second half of the year, supported by continued operational efficiencies, stronger field productivity, disciplined cost management, and a sustained recovery in the API business.

Dr. Sachin Patel, Managing Director & CEO, commented, “Q2 FY27 reflects a strong turnaround for the Company. We are pleased to report a return to operating profitability, with EBITDA of ₹5.58 crore at a 6.2% margin, compared with a loss in the year-ago quarter, and PAT of ₹7.06 crore against a loss last year. This improvement comes even as we continue to optimize our inventory pricing and cost structure and gives us confidence that our focus on productivity and operational efficiency is delivering results.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Themis Medicare Limited

Themis Medicare Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

THEMISMED
Healthcare › Drug Manufacturers - Specialty & Generic
APPROACHING SUPPORT
36
Fundamental
44
Technical
40
Overall

1W -0.35%
1M -6.69%
3M -3.77%
P/E: 23.3 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Themis moves sideways over three months, with neither buyers nor sellers taking control. Revenue contracts at -0.4% CAGR. That signals structural headwinds, not a short-term blip. No meaningful dividend — total return is entirely dependent on capital appreciation. RSI stands at 31, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at -0.4% yet the PEG reaches 99.00 — expensive for that growth. Furthermore, the stock drops 3.8% in three months. Neither value nor momentum supports this setup. It needs an earnings beat or a price reset first. Check Fundamentals of Themis Medicare Limited.

Continue Reading

GUJTHEM

Gujarat Themis Biosyn Limited Q2 FY27: Revenue Up 12% Yoy, New Facility Commissioned

Gujarat Themis Biosyn Limited (GUJTHEM) reports Q2 FY27 revenue up 12% YoY, new fermentation facility commissioned.

shalini shishodia tradealone

Published

on

Gujarat Themis Biosyn Limited Gujthem Q2 FY27 Results

Gujarat Themis Biosyn Limited (GUJTHEM) has reported robust financial results for Q2 FY27, with standalone revenue growing 12% year-on-year to Rs. 47.5 crore. The growth was primarily driven by strong volume momentum and a favorable shift in product mix towards Active Pharmaceutical Ingredients (APIs). The company’s new fermentation facility, commissioned during the quarter, marks a significant milestone in strengthening its manufacturing capabilities. Although the commissioning phase has had a near-term impact on operating margins, benefits from augmented capacity utilization are expected to become increasingly visible from Q4 FY27 onwards.

Quarterly Financial Highlights

During Q2 FY27, the company’s EBITDA stood at Rs. 8.5 crore, down 15.3% year-on-year, while EBITDA margins decreased by 1,210 basis points to 17.8%. The profit after tax (PAT) was Rs. 8.5 crore, down 40.6% YoY, with PAT margins dropping by 1,584 basis points to 17.8%. The company’s earnings per share (EPS) stood at Rs. 0.65 compared to Rs. 1.31 in the same quarter last year.

Half-Yearly Financial Performance

For H1 FY27, the company’s revenue grew 17% year-on-year to Rs. 91 crore. EBITDA increased 11% to Rs. 39 crore, while EBITDA margins declined by 235 basis points to 42.2%. The PAT for H1 FY27 was Rs. 19.5 crore, down 16.3% YoY, with PAT margins decreasing by 841 basis points to 21.4%. The EPS for H1 FY27 was Rs. 1.50 compared to Rs. 2.14 in the same period last year.

Dr. Sachin Patel, Managing Director, commented on the results, stating, ‘We are pleased to have commenced FY27 with healthy business momentum. As the new capacity moves towards higher utilization and the benefits of the acquisition begin to flow through, we expect operating performance to strengthen progressively. Our strategic priorities remain centered around precision fermentation, bioconversion, gene therapy, anti-infectives, and biopeptides, supported by capacity utilization, R&D-led product development, and a continued focus on operational efficiency. We believe these initiatives provide a strong platform for sustainable growth and value creation over the medium to long term.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

GUJTHEM
Healthcare › Drug Manufacturers - Specialty & Generic
CONSOLIDATING UP
52
Fundamental
60
Technical
56
Overall

1W +2.22%
1M -0.13%
3M +11.44%
P/E: 86.2 Cap: Mid
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Gujarat posts a 11.4% three-month gain, but softens in the last few weeks. Industry-leading margins of 28.0% reflect exceptional pricing power and operational efficiency. Revenue contracts at 3.8% CAGR. That signals structural headwinds, not a short-term blip. The stock gives back 0.1% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 3.8% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Gujarat Themis Biosyn Limited.

Continue Reading

Healthcare

Zydus Lifesciences Limited (zyduslife) Inspection by USFDA Concludes at Liqmeds, UK

Zydus Lifesciences Limited (ZYDUSLIFE) announces the closure of USFDA inspection at LiqMeds, UK with 4 observations.

Deputy Editor, Equities for tradealone

Published

on

Zydus Lifesciences Limited Zyduslife Inspection by USFDA

Zydus Lifesciences Limited (ZYDUSLIFE) announced the closure of a USFDA inspection at LiqMeds, UK. The inspection took place from 9th to 13th November 2026 and concluded with four observations. The company will work closely with the USFDA to address these observations expeditiously.

Inspection Details

The USFDA conducted an inspection at LiqMeds, UK, focusing on compliance and operational standards. The four observations noted during the inspection will be addressed promptly to ensure full compliance with regulatory requirements.

Company’s Response

Zydus Lifesciences Limited is committed to maintaining high standards of quality and compliance. The company will collaborate closely with the USFDA to resolve the observations identified during the inspection. This proactive approach aims to expedite the resolution process and uphold the company’s reputation for quality and integrity.

As a result, Zydus Lifesciences Limited remains focused on its mission to deliver high-quality pharmaceutical products globally. The company’s dedication to addressing regulatory observations underscores its commitment to continuous improvement and adherence to international standards.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zydus Lifesciences Limited

Zydus Lifesciences Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

ZYDUSLIFE
Healthcare › Drug Manufacturers - Specialty & Generic
CONSOLIDATING DOWN
86
Fundamental
62
Technical
75
Overall

1W -0.67%
1M +5.8%
3M +4.82%
P/E: 28.6 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.67 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock trades at 70% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.

Continue Reading

Trending

Exit mobile version